LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • IR Inquiries
Football Manager Guus Hiddink, receives arthritis surgery with MEDIPOST’s stem cell technology
2014/01/09
STEM CELL THERAPEUTIC

It became known that stell cell technology of Korea’s small hidden company was used in arthritis surgery on Foodball Manager Guus Hiddink.

Hiddink underwent arthritis surgery on his right knee with ‘CARTISTEM®’, MEDIPOST’s arthritis treatment drug of same type at Seoul JS Hospital on 9 January.

‘CARTISTEM®’ is a regenerative knee cartilage stem cell treatment drug for patients with degenerative osteoarthritis or osteoarthritis from repeated external injury, and in Korea it obtained KFDA approval in January 2012, surgeries with administration thereof occurring in more than 250 hospital including Samsung Seoul Hospital.

Number of administrations of CARTISTEM® was on average 20 odd cases per month in the initial stages, but has risen to more than 60 cases recently.

If knee joint is damaged, ultimately artificial joint surgery is required, and if ‘CARTISTEM®’ is administered, the damaged cells are regenerated.

Hiddink who loves golf other than soccer was recommended to undergo artificial joint surgery in hospital in Europe but it became known that one of the factors in the background to why he came to Korea is that with artificial surgery it will be difficult for him to enjoy golf anymore.

With Hiddink’s surgery, with trust in stem cell treatmet and Korean medical technology increasing, domestic and international demand of ‘CARTISTEM®’ is anticipated to expand further.

Industry personnel has disclosed that they “anticipate that it will become the catalyst to pioneer the domestic bio/pharmaceutical industry.

VIEW LIST

Related News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022/07/18

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
2022/05/31

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST